(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer...
Stats | |
---|---|
今日成交量 | 521 393 |
平均成交量 | 1.08M |
市值 | 467.70B |
EPS | KRW0 ( 2024-03-20 ) |
下一个收益日期 | ( KRW0 ) 2024-05-12 |
Last Dividend | KRW0 ( N/A ) |
Next Dividend | KRW0 ( N/A ) |
P/E | 0 |
ATR14 | KRW5.88 (0.13%) |
音量 相关性
SillaJen, Inc. 相关性
10 最正相关 |
---|
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
SillaJen, Inc. 相关性 - 货币/商品
SillaJen, Inc. 财务报表
Annual | 2023 |
营收: | KRW3.94B |
毛利润: | KRW-16.36B (-415.27 %) |
EPS: | KRW-198.16 |
FY | 2023 |
营收: | KRW3.94B |
毛利润: | KRW-16.36B (-415.27 %) |
EPS: | KRW-198.16 |
FY | 2022 |
营收: | KRW5.01B |
毛利润: | KRW-18.77B (-374.33 %) |
EPS: | KRW-239.25 |
Financial Reports:
No articles found.
SillaJen, Inc.
SillaJen, Inc. engages in the development and commercialization of oncolytic immunotherapy products. The company's lead product is Pexa-Vec, which is in Phase II clinical trial for the treatment of advanced liver cancer. It also develops JX-970 for the treatment of tumor tissues; and JX-900 is a series of modified vaccinia vaccine. The company was founded in 2006 and is headquartered in Seoul, South Korea.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。